A 52-Week Multi-Center Double-Blind Randomized Phase 2 Study of Seladelpar, a Potent and Selective Peroxisome Proliferator-Activated Receptor Delta (PPAR) Agonist, in Patients with Nonalcoholic Steatohepatitis (NASH) Uploaded: Nov 13, 2020 Type: PDF
The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice Uploaded: Aug 27, 2020 Type: PDF
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study Uploaded: Aug 27, 2020 Type: PDF
Seladelpar ENHANCE Phase 3 PBC Study Topline Results Uploaded: Aug 3, 2020 Type: PDF
Effects on Pruritus and Sleep Disturbance in Patients with Primary Biliary Cholangitis (PBC) after 1 Year of Treatment with Seladelpar, a Peroxisome Proliferator-Activated Receptor Delta Agonist: Results of an Open-label Phase 2 Study Uploaded: Jun 23, 2020 Type: PDF
